Joint Research Office


Updated JRO Brexit guidance

22 December 2020

The JRO has updated its position statement on our UCL clinical trials portfolio in relation to Brexit.

The update includes reference to the Northern Ireland Protocol – the current position is that Northern Ireland will remain in compliance with EU legislation and comply with EU requirements with respect to medicinal products and medical devices.

It also sets out information on freight services to support the uninterrupted delivery of medicines and medicinal products.

Earlier this year the JRO issued guidance setting out actions to be taken by UCL and UCLH investigators to prepare for the event of ‘no deal’ at the end of the transition period, and FAQs for researchers on planning for a possible ‘no deal.’

Researchers with questions can contact: uclh.jro-communications@nhs.net.